



MARKET RELEASE

9 July 2014

Phosphagenics Limited

TRADING HALT

The securities of Phosphagenics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 11 July 2014 or when the announcement is released to the market.

Security Code: POH

Kobe Li
Senior Adviser, Listings Compliance (Melbourne)

9 July 2014

Mr Kobe Zheng Li
Senior Adviser, Listings (Melbourne)
ASX Compliance Pty Ltd, Melbourne
Level 4
North Tower, Rialto
525 Collins Street
Melbourne, Vic, 3000



Email: zheng.li@asx.com.au

Dear Kobe

Re: Phosphagenics Limited
TRADING HALT

Phosphagenics Limited ("POH") requests a Trading Halt in accordance with Listing Rule 17.1

The reason for the Trading Halt request is that the Company expects to shortly make an announcement regarding a significant event relating to funding. Such announcement is expected to be made before the market opening on Friday 11 July 2014.

The Company is not aware of any reason why the Trading Halt should not be granted by the ASX nor is it aware of any other relevant information in relation to this request.

Yours Sincerely
Phosphagenics Limited



per Mourice Garbutt
Company Secretary
Poh/asx th 11.07.14

About Phosphagenics

Phosphagenics Limited is a biotechnology company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics Limited
ACN 056 482 403 ABN 32 056 482 403
11 Duerdin Street, Clayton VIC 3168
PO Box 1415, Clayton South MDC VIC 3169 Australia
Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151
www.phosphagenics.com Email: info@phosphagenics.com

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com

www.bioelixia.com